The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
Active, not recruiting · NCT04781192 · Registry updated 2026-01-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers | Advanced Biliary Tract Cancer | Active, not recruiting | Phase 1 / Phase 2 | 2026-01-23 | NCT04781192 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of Kansas Medical Center | 169 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The University of Kansas Medical Center | North Kansas City | United States | 1 |
| The University of Kansas Medical Center | Westwood | United States | 3 |
| University of Kansas Cancer Center - Lee's Summit | Lee's Summit | United States | 158 |
| University of Kansas Cancer Center - North | Kansas City | United States | 162 |
| University of Kansas Cancer Center - Overland Park | Overland Park | United States | 4 |